The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease

Smits, B., S. Goldacker, S. Seneviratne, M. Malphettes, H. Longhurst, O. E. Mohamed, C. Witt-Rautenberg, L. Leeman, E. Schwaneck, I. Raymond, K. Meghit, A. Uhlmann, C. Winterhalter, J. van Montfrans, M. Klima, S. Workman, C. Fieschi, L. Lorenzo, S. Boyle, S. Onyango-Odera, S. Price, M. Schmalzing, V. Aurillac, A. Prasse, I. Hartmann, J. J. Meerburg, M. Kemner-van de Corput, H. Tiddens, B. Grimbacher, P. Kelleher, S. Y. Patel, A. S. Korganow, J. F. Viallard, H. P. Tony, C. Bethune, H. Schulze-Koops, T. Witte, A. Huissoon, H. Baxendale, S. Grigoriadou, E. Oksenhendler, S. O. Burns, and K. Warnatz. 2023. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. J Allergy Clin Immunol 152: 528-537. doi: 10.1016/j.jaci.2022.12.813.

Categorised in:

This post was written by Heike Ufheil